🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input Page 4

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input

Admin Wed, Apr 16, 2025 at 7:09 AM 40 replies 1,896 viewsPage 4 of 8
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Apr 16, 2025 at 12:49 PM#16

Congrats KarenAZ_mom!! You should be so proud of yourself. 🎉

45 18emma_london, tammy_FL, Dr.LipidDallas and 42 others
Reply Quote Save Share Report
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Apr 16, 2025 at 1:06 PM#17

Admin's experience with SURPASS-CVOT tirzepatide resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I am on a different medication. But the overall trajectory has been remarkably similar. Down 43 lbs in 8 months.

One thing I would add that Admin did not mention: my sleep quality improved dramatically.

Last edited: Apr 16, 2025 at 3:06 PM
42 21james_edin, FranDenver, Dr.BariatricHTX and 39 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Apr 16, 2025 at 1:23 PM#18

Bookmarked 📌 The SURPASS-CVOT info in this thread is essential. Coming back to this for sure.

43 0RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 40 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Apr 16, 2025 at 1:40 PM#19

Clinical perspective on SURPASS-CVOT tirzepatide cardiovascular:

I have managed over 200 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.

For this specific question, I would recommend: reviewing the relevant clinical guidelines.

4 22tom_AK, josh_phd_bmore, roxy_nash and 1 other
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Apr 16, 2025 at 1:57 PM#20

Subscribing to this thread. SURPASS-CVOT tirzepatide is exactly what I've been researching. 🙏

46 8maria_elpaso, anders_CPH, Dr.NutriCornell and 43 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register